Eli Lilly
Eli Lilly's $800-mn Avid deal boosts diagnostic capabilities
09 Nov 2010
Privately held Avid is a developer of new molecular imaging agents that aid medical management of chronic human diseases
Privately held Avid is a developer of new molecular imaging agents that aid medical management of chronic human diseases